Login to Your Account



Other News To Note


Tuesday, January 24, 2012

• APP Pharmaceuticals Inc., of Schaumburg, ILL., and The Medicines Co. (MDCO), of Parsippany, N.J., settled litigation related to APP's abbreviated new drug application for a generic version of the anti-clotting drug Angiomax (bivalirudin for injection). MDCO licensed APP to begin selling APP's generic version of Angiomax in the U.S. on May 1, 2019, or earlier, in certain circumstances.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription